$TRAW
Traws Pharma, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022004015 Filed on March 21, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021
Revenue $56.00K $57.00K $226.0K
YoY Change -6.67% -13.64% -2.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.074M $2.284M $9.425M
YoY Change 16.52% 6.23% 13.15%
% of Gross Profit
Research & Development $1.745M $1.763M $7.297M
YoY Change -61.48% -57.95% -56.82%
% of Gross Profit
Depreciation & Amortization $4.000K $3.000K $14.00K
YoY Change 7.69%
% of Gross Profit
Operating Expenses $3.819M $4.047M $16.72M
YoY Change -39.48% -36.17% -33.71%
Operating Profit -$3.990M -$16.50M
YoY Change -36.4% -34.0%
Interest Expense $0.00 $530.0K $321.0K
YoY Change -100.0% 783.33% -252.86%
% of Operating Profit
Other Income/Expense, Net -$1.000K $7.000K $12.00K
YoY Change -96.67% -130.43% -75.0%
Pretax Income -$3.764M -$3.453M -$16.16M
YoY Change -41.46% -44.66% -35.74%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.764M -$3.453M -$16.16M
YoY Change -41.46% -44.67% -35.75%
Net Earnings / Revenue -6721.43% -6057.89% -7151.77%
Basic Earnings Per Share -$0.22 -$0.96
Diluted Earnings Per Share -$179.8K -$216.1K -$0.96
COMMON SHARES
Basic Shares Outstanding 20.89M 15.78M 16.83M
Diluted Shares Outstanding 15.98M 16.83M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.07M $59.38M $55.07M
YoY Change 189.84% 145.36% 189.84%
Cash & Equivalents $55.07M $59.38M $55.07M
Short-Term Investments
Other Short-Term Assets $35.00K $97.00K $332.0K
YoY Change -80.56% -87.88% -52.57%
Inventory
Prepaid Expenses
Receivables $28.00K $29.00K $28.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $55.43M $59.94M $55.43M
YoY Change 180.18% 139.74% 179.95%
LONG-TERM ASSETS
Property, Plant & Equipment $38.00K $42.00K $38.00K
YoY Change -26.92% -58.0% -62.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $12.00K $10.00K
YoY Change -93.33% -94.0% -95.0%
Total Long-Term Assets $48.00K $54.00K $48.00K
YoY Change -76.24% -73.0% -76.0%
TOTAL ASSETS
Total Short-Term Assets $55.43M $59.94M $55.43M
Total Long-Term Assets $48.00K $54.00K $48.00K
Total Assets $55.48M $59.99M $55.48M
YoY Change 177.58% 138.06% 177.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.757M $4.050M $2.757M
YoY Change -42.95% -28.95% -42.56%
Accrued Expenses $3.132M $2.749M $2.976M
YoY Change -36.88% -11.32% -38.0%
Deferred Revenue $226.0K $226.0K
YoY Change 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.115M $7.025M $6.115M
YoY Change -38.98% -24.46% -38.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.243M $3.299M $3.243M
YoY Change -14.66% -10.84% -14.66%
Total Long-Term Liabilities $3.243M $3.299M $3.243M
YoY Change -14.66% -10.84% -14.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.115M $7.025M $6.115M
Total Long-Term Liabilities $3.243M $3.299M $3.243M
Total Liabilities $9.358M $10.32M $9.358M
YoY Change -32.24% -20.58% -32.19%
SHAREHOLDERS EQUITY
Retained Earnings -$444.7M -$441.0M
YoY Change 3.77%
Common Stock $490.9M $490.6M
YoY Change 12.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.12M $49.67M $46.12M
YoY Change
Total Liabilities & Shareholders Equity $55.48M $59.99M $55.48M
YoY Change 177.58% 138.06% 177.39%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021
OPERATING ACTIVITIES
Net Income -$3.764M -$3.453M -$16.16M
YoY Change -41.46% -44.67% -35.75%
Depreciation, Depletion And Amortization $4.000K $3.000K $14.00K
YoY Change 7.69%
Cash From Operating Activities -$4.265M -$4.267M -$19.49M
YoY Change -22.03% -26.05% -15.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.50M $55.04M
YoY Change 507.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -35.00K 19.94M 55.56M
YoY Change -112.5% 633.24% 187.03%
NET CHANGE
Cash From Operating Activities -4.265M -4.267M -19.49M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -35.00K 19.94M 55.56M
Net Change In Cash -4.300M 15.68M 36.05M
YoY Change -17.15% -614.0% -1073.93%
FREE CASH FLOW
Cash From Operating Activities -$4.265M -$4.267M -$19.49M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$4.265M -$4.267M -$19.49M
YoY Change -22.03% -26.05% -15.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.17
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16832198
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11602391
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12396219
CY2021Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Liability
FairValueDisclosureOffbalanceSheetRisksAmountLiability
0
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12396219
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20895563
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001130598
CY2020Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
321000
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3243000
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3469000
CY2021Q4 us-gaap Liabilities
Liabilities
9358000
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36020
CY2021 dei Entity Registrant Name
EntityRegistrantName
Onconova Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-3627252
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
12 Penns Trail
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Newtown
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18940
CY2021 dei City Area Code
CityAreaCode
267
CY2021 dei Local Phone Number
LocalPhoneNumber
759-3680
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
CY2021 dei Trading Symbol
TradingSymbol
ONTX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q4 us-gaap Liabilities
Liabilities
13811000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444719000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
150000
CY2021Q4 us-gaap Assets
Assets
55478000
CY2020Q4 us-gaap Assets
Assets
19986000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2757000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4833000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3132000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4962000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
226000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
226000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6115000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10021000
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
true
CY2021Q2 dei Entity Public Float
EntityPublicFloat
109000000.0
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20895563
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55070000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19025000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
28000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
37000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
722000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
55430000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
19784000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20895563
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
209000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
124000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
490644000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
434593000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
369000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-428556000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
46120000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6175000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55478000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19986000
CY2021 us-gaap Revenues
Revenues
226000
CY2020 us-gaap Revenues
Revenues
231000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9425000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8326000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7297000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16898000
CY2021 us-gaap Operating Expenses
OperatingExpenses
16722000
CY2020 us-gaap Operating Expenses
OperatingExpenses
25224000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-16496000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-24993000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-321000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
208000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
48000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16163000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25153000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2021 us-gaap Profit Loss
ProfitLoss
-16163000
CY2020 us-gaap Profit Loss
ProfitLoss
-25157000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16832198
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11602391
CY2021 us-gaap Profit Loss
ProfitLoss
-16163000
CY2020 us-gaap Profit Loss
ProfitLoss
-25157000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
32000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-28000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
32000
CY2021 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-16191000
CY2020 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-25125000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11574000
CY2020 us-gaap Profit Loss
ProfitLoss
-25157000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
32000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9062000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
10294000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
1000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6175000
CY2021 us-gaap Profit Loss
ProfitLoss
-16163000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-28000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
576000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
55041000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
495000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
46120000
CY2021 us-gaap Profit Loss
ProfitLoss
-16163000
CY2020 us-gaap Profit Loss
ProfitLoss
-25157000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-321000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5510000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7319000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1916667
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26700000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
208000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
576000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
369000
CY2021 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-9000
CY2020 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-61000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-530000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
72000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2076000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
562000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1830000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1167000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-226000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-226000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19487000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23075000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55041000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9062000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
495000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10294000
CY2020 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
1000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55560000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19357000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-28000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36045000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3701000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19025000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22726000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55070000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19025000
CY2021 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Onconova Therapeutics, Inc. (the "Company") was incorporated in the State of Delaware on December 22, 1998 and commenced operations on January 1, 1999. The Company's headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. The Company believes that the product candidates in its pipeline have the potential to be efficacious in a variety of cancers with unmet medical need. The Company has the following two clinical-stage programs: 1. narazaciclib (ON 123300), a multi-kinase inhibitor in solid tumors; and 2. oral rigosertib alone or in combination with PD-1 inhibitors for treatment of KRAS-mutated solid tumors. During 2012, Onconova Europe GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 20, 2021, the Company amended its certificate of incorporation to effect a <span style="-sec-ix-hidden:Hidden_coKFgNsO6E-f8Kx8CYvKnA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-fifteen </span></span>reverse stock split of its common stock. All common stock, equity, share and per share amounts in the financial statements and notes have been retroactively adjusted to reflect this <span style="-sec-ix-hidden:Hidden_-nsrtUS8-UeOoQTUoC61Xw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-for-fifteen</span></span> reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 20, 2021, the Company amended its certificate of incorporation to decrease the number of authorized shares of common stock par value $0.01 per share from 250,000,000 to 125,000,000<span style="white-space:pre-wrap;">. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring operating losses since inception. For the year ended December 31, 2021, the Company incurred a net loss of $16,163,000 and as of December 31, 2021 the Company had generated an accumulated deficit of $444,719,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates and its preclinical programs, strategic alliances and its administrative organization. At December 31, 2021, the Company had cash and cash equivalents of $55,070,000. The Company will require substantial additional financing to fund its ongoing clinical trials and operations, and to continue to execute its strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2020, the Company closed on an offering of common stock. The Company issued 1,844,168 shares of common stock and net proceeds were approximately $9.0 million. In addition, during the year ended December 31, 2020 3,057,560 warrants were exercised, resulting in proceeds of $10.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 11, 2021, the Company closed on an offering of common stock. The Company issued 1,303,408 shares of common stock and net proceeds were approximately $8.5 million. On February 16, 2021, the Company closed on an offering of common stock. The Company issued 1,916,667 shares of common stock and net proceeds were approximately $26.7 million. On September 28, 2021, the Company closed on an offering of common stock. The Company issued 5,000,000 shares of common stock and net proceeds were approximately $19.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 20, 2021, the Company entered into an at-the-market equity distribution agreement for the sale of up to $25.0 million of common stock. Through September 30, 2021, the Company sold 109,523 shares under the agreement at a weighted average price of $5.32 per share. Net proceeds after commissions and offering expenses were approximately $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Following the unsuccessful conclusion of the INSPIRE trial, the Company took steps to reduce its cash expenditures. From September 2020 to December 2020, the Company implemented a workforce reduction of employees in research and development who were primarily focused on preparing the NDA for the use of rigosertib in higher risk </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">MDS. In total, 10 employees were terminated, representing approximately 43% of the Company’s workforce at that time. A severance related charge of approximately $1,207,000, which includes a non-cash charge of approximately $29,000<span style="white-space:pre-wrap;"> related to the accelerated vesting of outstanding stock options, was recorded in the year ended December 31, 2020. The accrued severance balance was included in accrued expenses and other liabilities on the balance sheet. </span>The accrued severance balance remaining at December 31, 2020 was $1,045,000 and was paid in periodic amounts through September 2021. On October 30, 2020, the Company notified its landlord of its intention to not renew its office space lease. The lease expired in February 2021 and was modified to a month-to-month lease for a portion of the space. The lease terminated in June 2021 and the Company has relocated to temporary office space with all employees working remotely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has and may continue to delay, scale-back, or eliminate certain of its research and development activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. The Company believes that its cash and cash equivalents will be sufficient to fund its ongoing trials and business operations for more than twelve months </span>from the date of this filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVID-19</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While the Company is not aware of a material impact from the novel coronavirus disease ("COVID-19") pandemic through December 31, 2021, the full extent to which COVID-19 will directly or indirectly impact the Company’s business, results of operations and financial condition, including manufacturing, clinical trials and research and development costs, depends on future developments that are uncertain at this time.</p>
CY2021Q4 ontx Number Of Clinical Programs In Programs
NumberOfClinicalProgramsInPrograms
2
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021 us-gaap Profit Loss
ProfitLoss
-16163000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444719000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55070000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1844168
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9000000.0
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3057560
CY2020 ontx Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
3057560
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10300000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1303408
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19500000
us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
10
us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.43
CY2021 us-gaap Severance Costs1
SeveranceCosts1
1207000
CY2021 us-gaap Accelerated Share Repurchases Adjustment To Recorded Amount
AcceleratedShareRepurchasesAdjustmentToRecordedAmount
29000
CY2020Q4 ontx Accrued Severance Costs
AccruedSeveranceCosts
1045000
CY2021 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-fifteen
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, other comprehensive income and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals, warrant liability, and allocation of consideration for revenue recognition. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2021Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
944585
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
253000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
263000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
35000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
180000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
332000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
731031
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2020Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
681614
CY2021 ontx Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
165000
CY2021 ontx Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
16506
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
500108
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
722000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
173854000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168344000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-16163000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-25157000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16832198
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11602391
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.17
CY2021Q4 ontx Operating Loss Carryforwards Indefinite Life
OperatingLossCarryforwardsIndefiniteLife
83192000
CY2021Q4 ontx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
15000
CY2020Q4 ontx Prepaid Research And Development Current
PrepaidResearchAndDevelopmentCurrent
189000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
29000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
90000
CY2021Q4 ontx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1759000
CY2020Q4 ontx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2541000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1217000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2239000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
156000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3132000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4962000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16153000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25167000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-10000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
14000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16163000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25153000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
4000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2018Q4 ontx Operating Loss Carryforwards Indefinite Life
OperatingLossCarryforwardsIndefiniteLife
83192000
CY2019Q4 ontx Operating Loss Carryforwards Indefinite Life
OperatingLossCarryforwardsIndefiniteLife
83192000
CY2020Q4 ontx Operating Loss Carryforwards Indefinite Life
OperatingLossCarryforwardsIndefiniteLife
83192000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
81468000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
76631000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
88721000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
87529000
CY2021Q4 ontx Deferred Tax Assets Tax Non Qualified Stock Options
DeferredTaxAssetsTaxNonQualifiedStockOptions
2194000
CY2020Q4 ontx Deferred Tax Assets Tax Non Qualified Stock Options
DeferredTaxAssetsTaxNonQualifiedStockOptions
2448000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1002000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1068000
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
4000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
4000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
447000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
647000
CY2021Q4 ontx Deferred Tax Assets Stock Appreciation Rights
DeferredTaxAssetsStockAppreciationRights
19000
CY2020Q4 ontx Deferred Tax Assets Stock Appreciation Rights
DeferredTaxAssetsStockAppreciationRights
19000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
173855000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168346000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.080
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.078
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.074
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.110
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.341
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.291
CY2021 ontx Effective Income Tax Rate Reconciliation Change In Deferred Tax Adjustment Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAdjustmentPercent
-0.026
CY2020 ontx Effective Income Tax Rate Reconciliation Change In Deferred Tax Adjustment Percent
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAdjustmentPercent
-0.105
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2021 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
576000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
369000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2020Q3 us-gaap Share Price
SharePrice
21.60
CY2020Q3 ontx Market Capitalization
MarketCapitalization
250000000
CY2020Q3 ontx Market Capitalization
MarketCapitalization
250000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11611829
CY2021Q1 ontx Market Capitalization
MarketCapitalization
600000000
CY2021 ontx Accumulated Sar Compensation Liability
AccumulatedSarCompensationLiability
66000
CY2019Q4 ontx Payment Of Clearing Fees
PaymentOfClearingFees
10000

Files In Submission

Name View Source Status
0001558370-22-004015-index-headers.html Edgar Link pending
0001558370-22-004015-index.html Edgar Link pending
0001558370-22-004015.txt Edgar Link pending
0001558370-22-004015-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex21d1.htm Edgar Link pending
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex31d2.htm Edgar Link pending
tmb-20211231xex32d1.htm Edgar Link pending
tmb-20211231xex32d2.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable